| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7598279 | SK LIFE | Neurotherapeutic azole compounds |
Oct, 2027
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11654133 | SK LIFE | Use of [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate in combination therapy |
Jun, 2039
(15 years from now) | |
Xcopri is owned by Sk Life.
Xcopri contains Cenobamate.
Xcopri has a total of 2 drug patents out of which 0 drug patents have expired.
Xcopri was authorised for market use on 10 March, 2020.
Xcopri is available in tablet;oral dosage forms.
Xcopri can be used as co-administration of cenobamate with phenobarbital and/or phenytoin for the treatment of partial onset seizures.
Drug patent challenges can be filed against Xcopri from 2024-03-10.
The generics of Xcopri are possible to be released after 16 June, 2039.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Mar 10, 2025 |
Drugs and Companies using CENOBAMATE ingredient
NCE-1 date: 2024-03-10
Market Authorisation Date: 10 March, 2020
Treatment: Co-administration of cenobamate with phenobarbital and/or phenytoin for the treatment of partial onset seizures
Dosage: TABLET;ORAL
XCOPRI family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic